Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based studyJavier Garciá Corbacho, Francesco Schettini, Laura Angelats et al.|Cancer Immunology Immunotherapy|2023Cited by 19
Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal studyJavier Garciá Corbacho, Francesco Schettini, Alberto Indacochea et al.|Cancer Immunology Immunotherapy|2025Cited by 3
Unexpected Durable Complete Response With Anti–PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker AnalysisDavid Pesántez, Javier Garciá Corbacho, Alberto Indacochea et al.|JCO Precision Oncology|2023Cited by 2